prbd News

Press Releases for Biosimilar_market

883

Gain a Deep Insight into the Global Healthcare Cold Chain Logistic Services Market

Driven by a strong demand of biopharmaceuticals, vaccines and clinical trial materials; the global market for healthcare cold chain logistic services is expected to grow exponentially in the coming years.
By : | 03-12-2012 | Health and Fitness:Healthcare | Total Views : 883
1308

Indian Immunodiagnostics Market to Grow at a CAGR of 11% in the Next Five Years

Driven by factors such as increasing popularity in preliminary testing, portability and ease of use; the market for Immunodiagnostics is expected to grow robustly in the coming years.
By : | 02-06-2012 | Medical:Medical | Total Views : 1308
1540

Biosimilar Insulin Products in the US to Grow at a CAGR of 74 Percent over the Period 2013-2020

Lantus is expected to be the most lucrative target for biosimilar manufacturers and account for 71% of the total biosimilar Insulin sales by 2020.
By : | 01-25-2012 | Industry:Industry | Total Views : 1540
924

Most of the Marketed Monoclonal Antibodies Lack a Patent Protection in India

Biosimilar manufacturers are currently free to copy and manufacture most of the globally marketed therapeutic monoclonal antibodies in India.
By : | 01-24-2012 | Health and Fitness:Health and Fitness | Total Views : 924
780

The Penetration of Biosimilars in the US Will Vary Across Different Biological Classes

The volume penetration of biosimilars in the US will strongly depend upon the complexity of the molecule, the patient pool that it caters and the extent of savings it brings to payers and providers
By : | 01-12-2012 | Health and Fitness:Health and Fitness | Total Views : 780
1076

New Report Suggests that Roche is Less Exposed to Biosimilars than Amgen

Excluding Mabthera, Roche’s other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020.
By : | 11-29-2011 | Medical:Medical | Total Views : 1076
795

Biosimilars for Blood Disorder Indications in the US Will Reach More Than US$ 2.4 Billion in 2020

Biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).
By : | 11-17-2011 | Business:Markets | Total Views : 795
1017

Biosimilar/Follow-on Monoclonal Antibodies: The Next Big Thing for Generic Manufacturers

With the patents of all major monoclonal antibodies set to expire during 2015 - 2020, Biosimilar (or Follow-on) Monoclonal Antibodies are expected to represent the next big thing for generic manufacturers.
By : | 11-02-2011 | Medical:Medical | Total Views : 1017
742

IMARC Group Releases the Most Robust Market Forecast on the US Biosimilar/Follow-on Biologics Market

With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be more akin to a marathon than a sprint.
By : | 10-25-2011 | Business:Business | Total Views : 742
914

The Market for Biosimilars Will be a Marathon and Not a Sprint

A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.
By : | 07-27-2011 | Health and Fitness:Health and Fitness | Total Views : 914

Page 1 of 1

TOP 10 PR Updates